Brief: Jw Therapeutics Announces Receipt Of Breakthrough Therapy Designation For Carteyva In Mantle Cell Lymphoma In China
03/04/2022 11:07
April 3 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* JW THERAPEUTICS ANNOUNCES RECEIPT OF BREAKTHROUGH THERAPY
DESIGNATION FOR CARTEYVA® IN MANTLE CELL LYMPHOMA IN CHINA
Source text for Eikon: ID:nPn1LnnPHa
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License